Photo from wikipedia
Routine categorization of DLBCL patients into GCB and non‐GCB groups by Hans' criteria could not accurately predict chemotherapy resistance and disease progression in patients treated with standard R‐CHOP therapy. There… Click to show full abstract
Routine categorization of DLBCL patients into GCB and non‐GCB groups by Hans' criteria could not accurately predict chemotherapy resistance and disease progression in patients treated with standard R‐CHOP therapy. There is a need to identify better biomarker predictors to enhance assisted selection of chemotherapy regimens for DLBCL patients.
Keywords:
resistance disease;
disease progression;
chemotherapy resistance;
chemotherapy
Journal Title: International Journal of Laboratory Hematology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: International Journal of Laboratory Hematology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!